Sirtex Medical Inc. Announces First Quarter Revenue U.S. sales of SIR-Spheres microspheres contribute to continued global growth Business Wire WOBURN, Mass. -- October 29, 2012 Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today that revenue from sales of SIR-Spheres^® microspheres in the U.S. grew 42 percent for the first quarter of fiscal year 2013 over the same period last year. Globally, the company reported dose sales grew 37 percent year-on-year for the first quarter of 2013. “The U.S. region delivered another excellent quarter which is a testament to the increasing awareness of this treatment option among the U.S. medical and patient communities,” said Mike Mangano, president of Sirtex Medical Inc. “We are continuing to develop our operations and availability in the Americas region so that more patients have access to Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres when they need it most.” Globally, dose sales increased in Asia Pacific 33 percent, while 26 percent growth was recorded in Europe. “This quarter represents the best quarter for sales growth in the history of our company and marks 33 consecutive quarters of dose sales growth,” Mangano continued. Today’s announcement is the latest in a series of positive reports from the Company, including the approval and launch of SIR-Spheres microspheres in Argentina earlier this month, the addition of multiple new treatment centers in the U.S. during the previous fiscal year, and the expansion of U.S. manufacturing capacity at the Wilmington, MA facility. For more information, visit www.Sirtex.com or find the latest updates on the SIR-Spheres microspheres Facebook page (www.Facebook.com/SIRSpheresmicrospheres). About Selective Internal Radiation Therapy using SIR-Spheres microspheres Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue. Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone. SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA PMA approval), the European Union (CE Mark), and Argentina (ANMAT). Additionally, SIR-Spheres microspheres are supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and Turkey. Available at more than 500 treatment centers, over 25,000 doses of SIR-Spheres microspheres have been supplied worldwide. For more information, visit www.sirtex.com. SIR-Spheres^® is a registered trademark of Sirtex SIR-Spheres Pty Ltd Contact: Fleishman-Hillard on behalf of Sirtex Medical Andrea Moody, 919-457-0743 Andrea.Moody@fleishman.com
Sirtex Medical Inc. Announces First Quarter Revenue
Press spacebar to pause and continue. Press esc to stop.